June 14, 2021
The American Medical Association (AMA) House of Delegates has elected Jack Resneck Jr., M.D., a dermatologist and health policy expert from San Francisco ,as the association’s president-elect. Following a year-long term as president-elect, Dr. Resneck will assume the office of AMA president in June 2022.
Dr. Resneck is a member of the AMA Board of Trustees and frequent spokesman on issues related to public health, having testified in in congressional hearings on the topics of telemedicine, digital health, rising prescription drug prices, prior authorization, and other challenges facing the U.S. health care system.
“It is truly an honor to be elected by my peers to lead the AMA, especially during this pivotal time of learning from the COVID-19 pandemic experience as we plan for the future of medicine and public health,” said Dr. Resneck.
“Now more than ever, I am proud to be part of an AMA that is dedicated to driving the future of medicine, removing obstacles to patient care, and leading the charge to prevent chronic disease and confront public health crises—all while prioritizing our goal of eliminating longstanding health inequities,” he added.
First elected to the AMA Board of Trustees in 2014, Dr. Resneck held the office of board chair from 2018 to 2019. Prior to serving on the board, Dr. Resneck chaired the AMA Council on Legislation and as a delegate in the AMA House of Delegates. Additionally, he has held several leadership positions in organized medicine, including president of the California Society for Dermatology and Dermatologic Surgery, board member at the American Academy of Dermatology, and is an active member of the California Medical Association.
In addition to caring for patients with a wide range of skin diseases in Northern California, Dr. Resneck has devoted his efforts to training the next generation of physicians. He is the vice chair and professor of dermatology at the University of California, San Francisco (UCSF) School of Medicine, where he directed the dermatology residency program for several years, with a joint appointment at the Philip R. Lee Institute for Health Policy Studies.